Physician profile
Ruby Jessica Rodriguez
NPI 1841950672
$1,356.34
in general payments reported to CMS, 2019-2025
16 companies · $764 in 2025
The $764 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $592 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,356.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $428.55 | 2024-2025 | Mounjaro, Kisunla, Zepbound |
| Novo Nordisk INC | $303.75 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $123.77 | 2025 | Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $91.88 | 2024-2025 | Rexulti |
| Abbvie INC. | $69.59 | 2024-2025 | |
| Dynavax Technologies Corporation | $58.37 | 2024-2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $55.51 | 2024 | |
| Sanofi-Aventis U.S. LLC | $41.04 | 2025 | |
| Glaxosmithkline, LLC. | $34.99 | 2024 | Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $28.38 | 2024 | |
| Janssen Biotech, INC. | $25.84 | 2024 | Tremfya |
| Amgen INC. | $22.48 | 2024 | Repatha, Otezla |
| Lundbeck LLC | $20.55 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.26 | 2024 | Ofev |
| Phathom Pharmaceuticals, INC. | $16.98 | 2024 | Voquezna |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.40 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.